Razavi International Journal of Medicine

Published by: Kowsar

Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial

Hasan Vosoghinia 1 , Abbas Esmaeilzadeh 1 , Azita Ganji 1 , Seyed Mousal-Reza Hosseini 1 , Saeid Amel Jamehdar 2 , Maryam Salehi 3 , Ali Bahari 1 , Omid Ghanaei 1 , Maryam Sahebari 4 , Farnood Rajabzadeh 5 , Kamran Ghaffarzadehgan 6 and Ladan Goshayeshi 1 , *
Authors Information
1 Department of Gastroenterology and Hepatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
2 Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
3 Department of Community Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
4 Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran
5 Department of Radiology, School of Medicine, Mashhad Branch, Islamic Azad University, Mashhad, IR Iran
6 Department of Pathology, Research and Education Department, Razavi Hospital, Mashhad, IR Iran
Article information
  • Razavi International Journal of Medicine: June 30, 2016, 4 (2); e36632
  • Published Online: May 21, 2016
  • Article Type: Research Article
  • Received: January 27, 2016
  • Revised: April 5, 2016
  • Accepted: April 28, 2016
  • DOI: 10.17795/rijm36632

To Cite: Vosoghinia H, Esmaeilzadeh A, Ganji A, Hosseini S M, Jamehdar S A, et al. Vitamin D in Standard HCV Regimen (PEG-Interferon Plus Ribavirin), Its Effect on the Early Virologic Response Rate: A Clinical Trial, Razavi Int J Med. 2016 ; 4(2):e36632. doi: 10.17795/rijm36632.

Copyright © 2016, Razavi Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Neal KR, Trent Hepatitis CG, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007; 56(8): 1098-104[DOI][PubMed]
  • 2. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010; 13(4): 306-12[PubMed]
  • 3. Khodabandehloo M, Roshani D. Prevalence of hepatitis C virus genotypes in Iranian patients: a systematic review and meta-analysis. Hepat Mon. 2014; 14(12)[DOI][PubMed]
  • 4. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3-6[DOI][PubMed]
  • 5. Kermani FR, Sharifi Z, Ferdowsian F, Paz Z, Zamanian M. Distribution of hepatitis c virus genotypes among chronic infected injecting drug users in Tehran, Iran. Jundishapur J Microbiol. 2013; 6(3): 265-8
  • 6. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009; 86(6): 902-8[DOI][PubMed]
  • 7. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014; 384(9941): 414-26[DOI][PubMed]
  • 8. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 9. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol. 2007; 22(6): 832-6[DOI][PubMed]
  • 10. Chopp S, Vanderwall R, Hult A, Klepser M. Simeprevir and sofosbuvir for treatment of hepatitis C infection. Am J Health Syst Pharm. 2015; 72(17): 1445-55[DOI][PubMed]
  • 11. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol. 2012; 18(8): 800-5[DOI][PubMed]
  • 12. Watkins RR, Lemonovich TL, Salata RA. An update on the association of vitamin D deficiency with common infectious diseases. Can J Physiol Pharmacol. 2015; 93(5): 363-8[DOI][PubMed]
  • 13. Iruzubieta P, Teran A, Crespo J, Fabrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol. 2014; 6(12): 901-15[DOI][PubMed]
  • 14. Van Belle TL, Gysemans C, Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player? Best Pract Res Clin Endocrinol Metab. 2011; 25(4): 617-32[DOI][PubMed]
  • 15. Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, et al. Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob Agents Chemother. 2007; 51(6): 2016-27[DOI][PubMed]
  • 16. Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, et al. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology. 2012; 56(4): 1231-9[DOI][PubMed]
  • 17. Petta S, Ferraro D, Camma C, Cabibi D, Di Cristina A, Di Marco V, et al. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther. 2012; 17(5): 823-31[DOI][PubMed]
  • 18. Luo YQ, Wu XX, Ling ZX, Cheng YW, Yuan L, Xiang C. Association between serum vitamin D and severity of liver fibrosis in chronic hepatitis C patients: a systematic meta-analysis. J Zhejiang Univ Sci B. 2014; 15(10): 900-6[DOI][PubMed]
  • 19. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol. 2011; 17(47): 5184-90[DOI][PubMed]
  • 20. Yokoyama S, Takahashi S, Kawakami Y, Hayes CN, Kohno H, Kohno H, et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J Viral Hepat. 2014; 21(5): 348-56[DOI][PubMed]
  • 21. Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, et al. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res. 2015; 35(1): 49-54[DOI][PubMed]
  • 22. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci. 2010; 55(9): 2624-8[DOI][PubMed]
  • 23. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010; 85(8): 752-7[DOI][PubMed]
  • 24. Terrier B, Lapidus N, Pol S, Serfaty L, Ratziu V, Asselah T, et al. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J Gastroenterol. 2015; 21(18): 5647-53[DOI][PubMed]
  • 25. Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J Hepatol. 2014; 61(6): 1247-52[DOI][PubMed]
  • 26. Berak H, Laskus T, Kolakowska-Rzadzka A, Wasilewski M, Stanczak JJ, Bardadin K, et al. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. Adv Med Sci. 2014; 59(2): 261-5[DOI][PubMed]
  • 27. Alavian SM, Ahmadzad M, Keshvari M. Efficacy and safety of interferon-alpha (PDferon B) and ribavirin combination therapy in patients with chronic hepatitis C in Iran. Hepat Mon. 2006; 6: 11-8
  • 28. Chen EQ, Shi Y, Tang H. New insight of vitamin D in chronic liver diseases. Hepatobiliary Pancreat Dis Int. 2014; 13(6): 580-5[PubMed]
  • 29. Jimenez-Sousa MA, Rallon N, Berenguer J, Pineda-Tenor D, Lopez JC, Soriano V, et al. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients. J Clin Virol. 2015; 65: 62-7[DOI][PubMed]
  • 30. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004; 80(6 Suppl): 1689S-96S[PubMed]
  • 31. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005; 289(1)-28[DOI][PubMed]
  • 32. Muller K, Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Investig Dermatol Symp Proc. 1996; 1(1): 68-71[PubMed]
  • 33. Hewison M. Vitamin D and the intracrinology of innate immunity. Mol Cell Endocrinol. 2010; 321(2): 103-11[DOI][PubMed]
  • 34. Trochoutsou AI, Kloukina V, Samitas K, Xanthou G. Vitamin-D in the Immune System: Genomic and Non-Genomic Actions. Mini Rev Med Chem. 2015; 15(11): 953-63[PubMed]
  • 35. Sabry D, Al-Ghussein MA, Hamdy G, Abul-Fotouh A, Motawi T, El Kazaz AY, et al. Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients. Ther Clin Risk Manag. 2015; 11: 279-88[DOI][PubMed]
  • 36. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology. 2011; 53(4): 1118-26[DOI][PubMed]
  • 37. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010; 51(4): 1158-67[DOI][PubMed]
  • 38. Lange CM, Gouttenoire J, Duong FH, Morikawa K, Heim MH, Moradpour D. Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-alpha. J Immunol. 2014; 192(12): 6037-44[DOI][PubMed]
  • 39. Duan X, Guan Y, Li Y, Chen S, Li S, Chen L. Vitamin D Potentiates the Inhibitory Effect of MicroRNA-130a in Hepatitis C Virus Replication Independent of Type I Interferon Signaling Pathway. Mediators Inflamm. 2015; 2015: 508989[DOI][PubMed]
  • 40. Alipour S, Saberi A, Seifollahi A, Shirzad N, Hosseini L. Risk factors and prevalence of vitamin d deficiency among Iranian women attending two university hospitals. Iran Red Crescent Med J. 2014; 16(10)[DOI][PubMed]
  • 41. Heshmat R, Mohammad K, Majdzadeh SR, Forouzanfar MH, Bahrami A, Omrani GHR. Vitamin D deficiency in Iran: A multi-center study among different urban areas. Iran J Public Health. 2008; 37
  • 42. Pinzone MR, Di Rosa M, Malaguarnera M, Madeddu G, Foca E, Ceccarelli G, et al. Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. Eur Rev Med Pharmacol Sci. 2013; 17(9): 1218-32[PubMed]
  • 43. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012; 56(1): 49-56[DOI][PubMed]
  • 44. Lambert AA, Drummond MB, Mehta SH, Brown TT, Lucas GM, Kirk GD, et al. Risk factors for vitamin D deficiency among HIV-infected and uninfected injection drug users. PLoS One. 2014; 9(4)[DOI][PubMed]
  • 45. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, et al. Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One. 2014; 9(2)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments